composed of the mureidomycins, 3 the napsamycins, 4 and the recently identified sansanmycins. 5 Sharing a characteristic structural feature, namely a 3′-deoxyuridine which is attached to a tetrapeptide moiety by an enamide linkage. These compounds exhibit selective antibacterial activity against Pseudomonas aeruginosa, a common nosocomial pathogen that is intrinsically resistant to a variety of drugs currently used in the clinic. Consequently, immuno-compromised patients are at greater risk of infection.
Moreover, the increased rate of acquired multidrug resistance in P. aeruginosa complicates anti-Pseudomonas chemotherapy, thereby making the development of novel antibacterial agents that are active against multi-drug resistance P. aeruginosa all the more urgent. [6] [7] [8] These uridylpeptide antibiotics are sub-nanomolar inhibitors of their biological target, the phospho-MurNAc-pentapeptide transferase (MraY), 2,9 which is responsible for the formation of lipid I in the peptidoglycan biosynthesis pathway.
2,10
Inhibition of the MraY by these antibiotics causes a malfunction of the peptidoglycan production in a manner different from β-lactams such as the carbapenems. Since MraY is an essential enzyme in bacteria 2 and a novel target, uridylpeptide antibiotics are expected to be highly useful anti-Pseudomonal agents. Intrigued by the promising 5 biological activity, several groups have conducted structure-activity relationship studies.
11-15
We have recently accomplished the total synthesis of pacidamycin D (1) and its 3′-hydroxyl analogue 2, which features a stereoselective construction of the Z-oxy-acyl enamide architecture by a copper-catalyzed C-N cross-coupling. 16 These compounds exhibited strong MraY inhibitory activity (IC 50 = 22 nM for 1, 42 nM for 2) and potent antibacterial activity against P. aeruginosa (MIC 8-64 μg/mL). Herein we describe the second-generation synthesis of 2 via a U-4CR in order to establish a convergent 6 synthetic strategy appropriate for the SAR study of uridylpeptide antibiotics. The biological evaluation of several analogues is also described.
Our second-generation retrosynthetic analysis of 2 is summarized in Scheme 1. We planned to install the N-terminal amino acid residue 3 on 4 in the final stage of the synthesis considering the initial efforts to prepare 2 as described later. We retrosynthetically divided 4 into the urea dipeptide 5, 2,4-dimethoxybenzylamine 6, the 2-N-methylaminopropionaldehyde derivative 7, and the α,β-unsaturated isonitrile derivative of uridine 8 for the U-4CR. This strategy allowed us to construct 4 with the non-proteinogenic amino acid α,β-diaminobutylic acid (DABA) residue, with linkages to the urea dipeptide and uridine moieties at the C-and N-termini. Moreover, the U-4CR strategy has the advantage of efficiently furnishing diastereomers that are useful for the SAR. Considering the nature of the multi-component assemblage, this strategy allows easy access to diversified analogues.
The aldehyde unit 7 was prepared as shown in Scheme 2. Namely, N-formyl-L-alanine 9 was reduced by LiAlH 4 , and the resulting N-methylaminoalcohol was selectively protected by a Boc group to provide 10 in 98% yield over 2 steps. The primary hydroxyl group of 10 was oxidized by Dess-Martin periodinane to give 7 in 84% yield. With 7 and 8 in hand, we then examined the assemblage of the four components by the U-4CR (Scheme 4). The assemblage proceeded simply by mixing 5, 6, 7, and 8 in EtOH at room temperature for 48 h, and the desired 13 and its diastereomer at the newly formed stereogenic center were obtained in acceptable yields (33% for 13 and 30% for 14). These were separated by silica gel column chromatography. Initially we planned to use an aldehyde of the dipeptide derivative such as 21, which was prepared by reduction of the Weinreb amide derivative of the dipeptide 20, as the aldehyde component in the U-4CR assemblage (Scheme 5). However, it turned out that the resulting aldehyde 21 easily cyclized to form a rather stable cyclic aminal 22, and the U-4CR did not proceed at all. Therefore we turned our attention to the stepwise synthetic route toward the target compounds as shown in Scheme 4 in order to avoid the undesired cyclization. and the results are summarized in Table 1 . It turned out that the epimer 19 was much 10 weaker than the MraY inhibitors 1 or 2 with an IC 50 value of 4000 nM. The stereochemistry at the DABA residue was very important for enzyme inhibitory activity.
This was also true for the analogues 30 and 31, which possess the same stereochemistry at the DABA residue (IC 50 650 and 8900 nM, respectively). Analogue 27a showed similar inhibitory activity (IC 50 22 nM) to that of 1 and 2, and introducing the Gly-L-m-Tyr moiety at the N-terminus did not improve but instead retained the activity.
However, moving the hydroxyl group to the para-position at the N-terminal phenyl ring resulted in a large decrease in inhibitory activity with an IC 50 value of 4000 nM for 27b.
Therefore the position of the hydroxyl group on the phenyl ring plays a crucial role.
Analogue 27c showed a slight decrease in MraY inhibitory activity. The antibacterial activity of 2, 19, 27a-c, 30, and 31 was then evaluated against a range of clinically isolated P. aeruginosa strains (Table 2) . 20 The overall antibacterial activity was well correlated to the MraY inhibitory activity. Thus, 27a showed a similar anti-Pseudomonal activity to that of 1 and 2, whereas 19, 27b, 27c, 30, and 31 exhibited no activity up to 32 μg/mL. The exception was the Gly analogue 27c, which showed no anti-Pseudomonal activity in spite of potent MraY inhibitory activity (Table 1, IC 50 65 nM).
In summary, the second-generation synthesis of 2 has been accomplished via a U-4CR at a late stage of the synthesis. This approach provided ready access to a range of analogues including the diastereomers of the DABA residue and hybrid-type analogues of the mureidomycins. Biological evaluations of these analogues indicated that the stereochemistry at the DABA residue has a significant impact on both the MraY biochemical inhibition and whole-cell antibacterial activity. Table 1 . MraY Inhibitory Activity of 3'-Hydroxypacidamycin Analogues Table 2 . Anti-Pseudomonal Activity of 3'-Hydroxypacidamycin Analogues
